title: First-line first? Trends in thiazide prescribing for hypertensive seniors.
abstract: BACKGROUND
  Evidence of reduced cardiovascular morbidity and mortality as well as cost support thiazide diuretics as the first-line choice for treatment of hypertension. The purpose of this study was to determine the proportion of senior hypertensives that received thiazide diuretics as first-line treatment, and to determine if cardiovascular and other potentially relevant comorbidities predict the choice of first-line therapy.
  
  
  RESULTS
  British Columbia PharmaCare data were used to determine the cohort of seniors (residents aged 65 or older) who received their first reimbursed hypertension drug during the period 1993 to 2000. These individual records were linked to medical and hospital claims data using the British Columbia Linked Health Database to find the subset that had diagnoses indicating the presence of hypertension as well as cardiovascular and other relevant comorbidities. Rates of first-line thiazide prescribing as proportion of all first-line treatment were analysed, accounting for patient age, sex, overall clinical complexity, and potentially relevant comorbidities. For the period 1993 to 2000, 82,824 seniors who had diagnoses of hypertension were identified as new users of hypertension drugs. The overall rate at which thiazides were used as first-line treatment varied from 38% among senior hypertensives without any potentially relevant comorbidity to 9% among hypertensives with previous acute myocardial infarction. The rate of first-line thiazide diuretic prescribing for patients with and without potentially relevant comorbidities increased over the study period. Women were more likely than men, and older patients were more likely than younger, to receive first-line thiazide therapy.
  
  
  CONCLUSIONS
  Findings indicate that first-line prescribing practices for hypertension are not consistent with the evidence from randomized control trials measuring morbidity and mortality. The health and financial cost of not selecting the most effective and least costly therapeutic options are significant.
authors.affiliation: Centre for Health Services and Policy Research, University of British Columbia, Vancouver, Canada. morgan@chspr.ubc.ca
authors.forename: Steve
authors.initials: S
authors.lastname: Morgan
authors.forename: Kenneth L
authors.initials: KL
authors.lastname: Bassett
authors.forename: James M
authors.initials: JM
authors.lastname: Wright
authors.forename: Lixiang
authors.initials: L
authors.lastname: Yan
mesh_terms: D000367:Age Factors; D000368:Aged; D000959:Antihypertensive Agents / Q000191:economics / Q000627:therapeutic use*; D001955:British Columbia; D015331:Cohort Studies; D016527:Drug Costs; D011307:Drug Prescriptions; D005260:Female; D006801:Humans; D008297:Male; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D012737:Sex Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000191:economics / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D049993:Sodium Chloride Symporter Inhibitors